Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Acceleration of diabetic wound healing

a wound healing and acceleration technology, applied in the field of acceleration of diabetic wound healing, can solve the problems of amputation of lower limbs, and inability to accelerate wound healing, so as to accelerate the healing process of wounds

Active Publication Date: 2017-09-28
UNIV OF NOTRE DAME DU LAC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a method for accelerating wound healing and treating diabetic wounds by using an enzyme called MMP-8. The inventors found that MMP-8 is active in wounds of non-diabetic and diabetic mice, and that MMP-9 is upregulated only in diabetic wounds. When treated with a selective MMP-8 inhibitor, diabetic wounds took longer to heal. However, selective inhibition of MMP-9 or ablation of the MMP-9 gene led to acceleration of wound healing in diabetic mice. Furthermore, treatment of wounds with MMP-8 accelerated wound healing in both diabetic and non-diabetic animals. The patent also provides a composition for accelerating wound healing by contacting an open wound with MMP-8 and a selective MMP-9 inhibitor. The selective MMP-9 inhibitor should have at least 0.5 μM smaller Ki value for MMP-9 than for MMP-8.

Problems solved by technology

A complication in diabetic patients is the inability of wounds to heal, which resulted in 73,000 lower-limb amputations in the United States in 2010.
There is currently no pharmacological therapeutic available that accelerates wound healing without significant adverse effects.
Hence, wound healing is impaired and delayed in diabetic patients.
However, this process is not well understood and the actual instigator MMPs is not known.
Chronic wounds in diabetic patients are a devastating complication of diabetes that can lead to amputations or even death.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Acceleration of diabetic wound healing
  • Acceleration of diabetic wound healing
  • Acceleration of diabetic wound healing

Examples

Experimental program
Comparison scheme
Effect test

example 1

and Analysis of MMP Inhibitors

[0125]Synthesis of ND-336. The synthesis of ND-336 is shown in Scheme 1. The reaction of 4-mercaptophenol (2) with allyl bromide (1) produced compound 3, which was allowed to react with 4-fluorobenzonitrile to afford diphenyl ether 4 in good yields (94% and 82% for the first and second steps, respectively). Subsequent reduction of the nitrile with LiAlH4, followed by Boc-protection of the resultant amine yielded compound 5, which was oxidized to the corresponding oxirane 6. The reaction of 6 with thiourea produced the Boc-protected thiirane 7. After the final acid Boc-deprotection, the desired ND-336 was in hand as the HCl salt.

Other MMP-9 inhibitors can be prepared by the methods described in U.S. Pat. No. 6,703,415 (Mobashery et al.); U.S. Pat. No. 7,114,917 (Mobashery et al.); U.S. Pat. No. 7,928,127 (Lee et al.), U.S. Pat. No. 8,093,287 (Lee et al.); and U.S. Pat. No. 8,937,151 (Chang et al.); U.S. Patent Publication No. 2013 / 0064878 (Chang et al.);...

example 2

ion of Diabetic Wound Healing Using a Novel Protease-Anti-Protease Combination Therapy

[0138]Enzyme Inhibition Studies.

[0139]Human recombinant active MMP-2 and MMP-7, and the catalytic domains of MMP-3 and MMP-14 / MT1-MMP were purchased from EMD Chemicals, Inc. (San Diego, Calif., USA); human recombinant catalytic domains of MMP-1, MMP-8, and MMP-9 were purchased from Enzo Life Sciences, Inc. (Farmingdale, N.Y., USA); human recombinant active ADAM9 and ADAM10 were purchased from R&D Systems (Minneapolis, Minn., USA). Fluorogenic substrates MOCAc-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 (for MMP-2, MMP-7, MMP-9 and MMP-14) and MOCAc-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2 (for MMP-3) were purchased from Peptides International (Louisville, Ky., USA); Mca-KPLGL-Dpa-AR-NH2 (for MMP-1, MMP-8 and ADAM10) and Mca-PLAQAV-Dpa-RSSSR-NH2 (for ADAM9) were purchased from R&D Systems (Minneapolis, Minn., USA). The Km values for MMP-2, MMP-9 and MMP-14 were the same as previously reported by G...

example 3

tical Dosage Forms

[0165]The following formulations illustrate representative pharmaceutical dosage forms that may be used for the therapeutic or prophylactic administration of a compound, enzyme, or composition described herein, or a pharmaceutically acceptable salt, solvate, or composition thereof (hereinafter referred to as ‘Compound X’):

(i) Tablet 1mg / tablet‘Compound X’100.0Lactose77.5Povidone15.0Croscarmellose sodium12.0Microcrystalline cellulose92.5Magnesium stearate3.0300.0

(ii) Tablet 2mg / tablet‘Compound X’20.0Microcrystalline cellulose410.0Starch50.0Sodium starch glycolate15.0Magnesium stearate5.0500.0

(iii) Capsulemg / capsule‘Compound X’10.0Colloidal silicon dioxide1.5Lactose465.5Pregelatinized starch120.0Magnesium stearate3.0600.0

(iv) Injection 1 (1 mg / mL)mg / mL‘Compound X’ (free acid form)1.0Dibasic sodium phosphate12.0Monobasic sodium phosphate0.7Sodium chloride4.51.0N Sodium hydroxide solutionq.s.(pH adjustment to 7.0-7.5)Water for injectionq.s. ad 1 mL

(v) Injection 2 (10 m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
residence timesaaaaaaaaaa
residence timesaaaaaaaaaa
residence timesaaaaaaaaaa
Login to View More

Abstract

The invention provides compounds, compositions, and methods to improve or accelerate the healing of a wound. In various embodiments, the methods can include the topical treatment of the wound with the enzyme MMP-8, or the topical treatment of the wound with MMP-8 in combination with administration of an MMP-9 inhibitor, to accelerate the healing of the wound.

Description

RELATED APPLICATIONS[0001]This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application Nos. 62 / 052,921, filed Sep. 19, 2014, and 62 / 128,871, filed Mar. 5, 2015, which applications are incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]Diabetes affects 340 million people in the world, including 29.1 million individuals in the United States. A complication in diabetic patients is the inability of wounds to heal, which resulted in 73,000 lower-limb amputations in the United States in 2010. The standard treatment for diabetic foot ulcers includes debridement of the wound, treatment of infection with antibiotics, and reducing or eliminating weight pressure from the lower extremities. There is currently no pharmacological therapeutic available that accelerates wound healing without significant adverse effects.[0003]In diabetic patients, high blood sugar triggers prolonged chronic inflammation, with concomitant elevated levels of matrix met...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/43A61K38/17A61K9/06
CPCA61K38/43A61K9/06A61L2300/434A61K9/0014A61K38/17A61K9/0019A61K9/12A61K9/2054A61K9/4866A61K47/02A61K47/06A61L15/44
Inventor CHANG, MAYLANDMOBASHERY, SHAHRIAR
Owner UNIV OF NOTRE DAME DU LAC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com